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THE CARDIAC CATHETERIZATION COMMITI.EE 
Preamble 
Method oftapic selection. This expert consensus document 
on coronary artery stems was developed at the request of the 
Technology and Practice Executive Committee because of a 
major increase in interest in this area. The Expert Consensus 
document is intended to inform practitioners, payers and other 
interested parties of the opinion of the American College of 
Cardiology (ACC) concerning evolving areas of clinical prac- 
tice and/or technologies that are widely available or are new to 
the practice communi@ Topics chosen for coverage by Expert 
Consensus documents are so designated because the evidence 
base and experience with the technology or clinical practice are 
not sufficiently well developed to be evaluated by the formal 
ACCIAmerican Heart Association (AHA) Practice Guidelines 
process, Thus, the redder should view the Expert Consensus 
documents as the best attempt of the ACC to inform and guide 
clinical practice in areas where rigorous evidence is not yet 
available. Some topics covered by Expert Consensus docu- 
ments Will be addressed subsequently by the ACCIAHA Prac- 
tice Guidelines process. 
Introduction 
More than 400,000 Americans and 800,000 patients world- 
wide undergo a nonsurgical coronary artery interventional 
procedure each year. Although only introduced in the 1990s in 
some iahoratories intracoronary stents are used in ~50% of 
these patients. 
This rapid growth creates important limitations to analysis 
of currently available data by the writing committee. The rapid 
growth in the use of stents has come largely in treatment 
categories not included in the few controlled clinical trials 
available (e.g., multiple stents, restenotic lesions). The three 
completed controlled trials used a single type of stem (Palmaz- 
Schatz) in relatively small sample sizes. The techniques em- 
ployed to expand the stents and anticoagulant therapy used in 
current practice have been substantially modified from those 
used in these trials. Furthermore, most of the remaining 
published reports concern small, retrospective studies. Finally, 
because stent technology and practice are in rapid evolution, 
part or all of this document will require updating in the near 
future, 
History of Intravascular and Coronary Stent Use 
Although first proposed by Dotter in 1969 (I), the design 
and nonsurgical placement of an arterial endoprosthesis in 
-- 
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patients was’ delayed until the early 19gOs (2.3). Further 
the American College of Cardiology in June 1996. modifications led to self-expanding and balloon-expandable 
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Table 1. Current Designs: Coronary Artery Stents That Are Food and Drug Administraticm Approved or Undergoing Testing (in 
alphabetical order) 
.- 
Delive~Expansion 
Stent Structure Method Materials 
__-- 
ACS MultiLink Rings joined by linked, etched tube Balloon 316L SS 
ACT one Slotted tube Balloon Nitinol 
AngioDynamics/AngioStent Single wire, simple coil Balloon Platinum/iridium 
Angiomcd--‘JSCK Multiple-wire braid Self Nitho! 
AVI? Microstent Wire zigzags; weldediunwelded in series Balloon 316L ss 
BeStent (Medtronic) Slotted tube BallooR 3162 YS 
Duke Biodegradable Stent NA WA NA 
Cook Gianturc+Roubin Flex Stent* Flexible coil stent Balloon 316L ss 
Cordis Single sinusoidal helical coil Balloon Tantalum 
Global Therapeutics Freedom Stent Wire mesh Balloon 316LSS 
INSTENT’CardioCoil Single wire, simple coil Self Nirinol 
lsostent (Fischell) Johnson & Johnson sfcnt dosed with radioactivity Balloon Coated with radioactive isotope 
Johnson & Johnson Palmaz-Schatz’ Slotted tube &lkOfl 346L ss 
Mayo Stem Fibrin-wallled metallic stent Bailoon Tantalum 
Medivent-Schneider Wallstent Multiple-wire braid Self Eligiloy (cobalt-based alloy) 
Pviedtronic Wiktor Single-wire sinusoida! helix Balloon Tantalum 
NIR Stem (SCIMED/Medinol) Slotted tube Balloon 346L SS 
SCfMED Slotted tube Balloon Nitinol 
*Food and Drug .A&lini;~iarinn appi0.c . (2 d NA = not available at this time; SS = stainless steel. 
first series of stent (Walistent) implants in the coronary 
arteries of patients. After this landmark study, the Food and 
Drug Administration (FDA) approved the first Phase 1 trial 
using an intracoronary stent. By 1991, Gay et al. (6) and 
Sierruys et al. (7) described a high rate of stent thrombosis with 
one stent configuration at intermediate follow-up, and Buch- 
wald et al. (8) described initial results with another stent. In 
1993, the FDA granted approval for use of the Gianturco- 
Roubin stem for treatment of acute or threatened closure 
during coronary intervention. In 1994, the Palmaz-Schatz stent 
was approved by the FDA for use 
in a group of selected patients cligibie for balloon angioplasty 
with symptomatic ischemic heart disease due to discrete (length 
less than 15 mm), de no~o (non-restenotic) native coronary 
artery lesions with a reference vessel diameter in the range of 
.3-J mm. In this patient population, stenting . . . produces a 
larger luminal diameter, maintains artery patency, and reduces 
the incidence of restenosis at six months, as compared with 
balloon angiopaasty. 
In clinical practice, use of coronary artery stents has been 
expanded to a variety of non-FDA approved indications, which 
are discussed below. No previous ACC documents have ad- 
dressed stent use in coronary arteries. 
A number of coronary stents are being developed and 
tested. The two FDA-approved stents, as well as those being 
tested, fall into two broad groups of devices based’on the 
method of delivery and expansion within the coronl?ty artery: 
I) balloon-expandable, and 2) self-expanding~(Table I). 
e 
Balloon-expandable stents. The two FDA-approved stents 
(e.g., Gianturco-Roubin and Palmaz-Schatz) and the majoe? 
of stents being tested at this time are balloon-expandable. 
These stents are mounted on an angioplasty balloon cath- 
eter and delivered either with (Palmaz-Schatz) or without 
(Gianturco-Koubin) a protective sheath. There are two major 
groups of balloon-expandable stents. They include 1) metaihc 
coils, and 2) slotted-tube designs. 
b4dlic coil, The prototype coil design is the Gianturcc% 
Roubin stent (Cook, Inc.). This stem has an interdigitating 
coiled structure of 0.15-mm surgical stainless steel (9). The 
current model is only faintly visualized during fluoroscopy, 
varies in length (12 and 20 mm) and is quite flexible but is 
easily deformed or damaged as currently delivered. Newer 
models have radiopaque markers at both ends, The Wiktor 
coiMype stent (Medtronic, Inc.), also delivered without a 
sheath, is made of single radiopaque tantalum wire !vith a 
sinusoidal wave pattern configured as a crimped heli. This 
stent has good longitudinal flexibility, which facilitates use in 
tottuous vessels (10,21). 
Balloon-expandable stems under evaluation differ in length 
(e.g., some are very short but can be combined to pr&de stent 
support to a variable length appropriate, to individual case 
needs), materials used (e.g.> nitinoil), types of wire and specific 
wire configuration (e.g., short-wave Wiktor vs. regular-wave 
Wiktor). These differences affect ,device performance, diliver- 
ability, fiexibih& radial strength and radiopacity. Vilhether 
these differences will be clinically important (e.g., ease of 
deliverability in’diseased and tortuous arteries, thromb$genis- 
ity, tissues reaction) remains to be determined, 
Slmed tubes. The prototype: sknted-tube design j is the 
Palmax-Schatz stent (Johnson & ‘Johnson, ~~t~~~nti~~?~ j& 
terns), constructed of 0.%)7&m St~~iul!~~‘stees:con~gu.~~ mto,8’3 / j: ,._ ;’,i. 8’ ‘4 i ‘>, $~ r 
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tube with rectangular slots (12). During balloon expansion, the 
slots enlarge to become diamond shaped. At present, different 
lengths of this stem are available in Europe but not in the 
United States. The most frequently used stent is 15 mm long 
with an arFiculation at the midpoint to improve flexibility and 
ease of delivery (13). Qther slotted tubular-type stents being 
evaluated vary by type of material used, design and length. 
Self-expanding. The prototype seif-expanding stem is the 
multifilament woven stainless teel alloy Wallstent (Medinvent- 
Schneider, Lmsanne, Switzerland), which is e.longated and 
constrained on the delivery catheter by a ‘rolling membrane 
sheath. Retraction of the sheath results in stent self-expansion. 
Although this was the first type of stent used in human 
coronary arteries (5) subsequent application was delayed by a 
high thrombosis rate (6,7,14), which appears to have been the 
result of suboptimal implantation and anticoagulation regi- 
mens (15). Numerous other self-expanding stems are currently 
under evaluation (Table 1). 
Akthodology in Development 
Devices in testing are smaller, more flexible and more 
radiopaque. Stent coatings (e.g., heparin, collagen, fibrin) 
designed to decrease the potential for restenosis and acute 
thrombosis are being tested. Biostable and biodegradable 
polymers are also under evaluation, but at present have been 
limited by polymer-induced inflammation. Local radiation to 
reduce smooth muscle cell hyperplasia, and other forms of 
energy to ‘“seal” or bond tissue flaps resulting from dissection 
31~0 are under investigation. 
of stenting in these situations would be premature. Conse- 
quently, the language of this document reflects the quality of 
evidence currently available. 
Clinicd Outcomes: Recommendations for 
Use of Coronary stenting 
To Improve Outcomes of Percutaneous 
Transluminal Coronaq Angioplasty 
Acute results. Stenting increases minimal coronary iumen 
diameter to a greater degree than percutaneous transluminal 
coronary angioplasty (PICA) alone, according to the results of 
two randomized trials using the Paimaz-Schatz stent (16,17). 
These trials compared two initial treatment strategies: stenting 
alone and PICA with “stent backup” if needed. Both trials 
were restricted to use of a single stent placed at a nonrestenotic 
lesion site in vessels ~3.0 mm in diameter with lesions 51.0 cm 
in length. Patients (STRESS n = 410; BENESTENT n = 520) 
were randomly assigned to either stenting or PTCA. In both 
trials, stent-assigned patients had a larger lumen diameter than 
PTCA-assigned patients immediately after the procedure (2.49 
vs. 1.99 mm for STRESS, 2.48 vs. 2.05 mm for BENESTENT, 
respectively). In the STRESS (17) trial, there was a significant 
difference in successful angiographic outcome in favor of 
stenting (96.1% vs. 89.6%). The STRESS trial showed a 
nonsignificant trend for an increase in access ite complications 
with stenting (7.3% vs. 4.0%, p = 0.14) but in the BENEST- 
ENT study this trend was significant (13.5% vs. 2.1%) and was 
associated with a significantly longer hospit:) stay (S.5 vs. 3.1 
days). 
Method of Data Collection 
Coronary stents for elective applications have been in 
general clinical use only since 1993. The published reports 
evaluating appropriate indications, outcomes and economics is 
limited. The writing group identified >300 English-language 
publications dealing with human studies for initial review. Our 
review identified only four completed randomized clinical 
trials: the Stent Restenosis Study (STRESS) I and II, the 
Belgium-Netherlands Stent (BENESTENT) trial, the Saphe- 
nous for Vein Gtaft Lesions De Novo (SAVED) trial and the 
Intracoronary Stenting and Antithrombotic Regimen (ISAR) 
trial. In addition, the Writing Group considered published 
studies of excellent quality. The writing group also considered 
material that was submitted,for publication if, in the group’s 
‘opinion, the submitted work would merit peer-review publica- 
tion, Data available only inmabstract form were infrequently 
considered in this document, Data on volume use and techni- 
cal specifications were requested directly from manufacturers. 
When “appropriate, these data were incorporated into the 
document. The writing ‘group recommends that a number of 
controlled clinical’ trials with results not yet available be 
followed closely (Table 2). 
In many areas, ~clinical evidence is still inadequate. The 
_, group concluded tl$ publishrng firmrecommendations for use 
Although neither trial was large enough tq? detect a di&r- 
ence in rates of either acute myoeardial inlrction (MI) or 
death, no systematic approach to detect myocardial damage 
was used in these trials. This limitation could be important 
because several recent reports have suggested that “microne- 
crosis,” defined as postintervention elevation of crcatine kinase 
(CK) or CK-MB fraction, may occur in 10% to 15% of 
coronary interventional procedures, including Stenting (l&19) 
and is associated with an increase in risk for death over 
long-term follow-up (l&20). 
Intermediate-term results. Follow-up data are very limited 
with regard to both patient numbers and duration. At 6 months 
after the procedure, both randomized trials found that stent- 
assigned patients had a larger lumen diameter and lower 
restenosis rate than those assigned to#PTCA. The STRESS 
trial showed no difference ‘in adverse outcomes (death, MI, 
coronary artery bypass graft surgery [CABG], vessel closure or 
second revascularization), whereas the somewhat larger 
BENESTENT trial reported reduced adverse outcomes 
(death, MI, cerebrovascular accident, CABG or second revas- 
cularization) in stent-assigned patients (p = 0.02). Thust 
clinical benefit was largely the result of reduced need for 
repeat revascularization, Event-free survival favored those 
patients assigned to stenting (STRESS 81% vs. 73% p = 0.16; 
BENESTEh@‘7?% vs. 67%; p < 0.093). @e-year follow-up. ,~ 
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Table 2. Clinical ‘Trials of Coronary Sterns Under Wa.y or Proposed 
Tri31 Objective 
___- 
Design Sample size Principal fnvestinator 
ACS .MultiLink” 
ACf One” 
Angiostent 
BEh’ESTENT II 
CardioCoil 
DlSTRESS 
EASJ 
Epilog Stent 
Substudy 
ERASER 
GRACE 
GR-II 
GR-II Registw 
HIPS 
LAWS 
MULTJLJNR- 
USA 
MUSIC 
OPTIMAL 
OSTJ 
PAM1 
POST 
RAVES 
REST I, II 
SCRlPPS 
SMART 
SPORT 
STARS 
STARS Registry 
START 
Reduced STRESS 
STRUT 
TOASC 1, II, Ill 
TECBEST 
Wallstent 
WEST I, I1 
Wiktor 
Comparison of multilink stem vs. JJJS 
Evaluation of nitinol stent 
Evaluation of Angiostent 
Comparison of PTCA vs. heparin-coatrd JJIS 
Evaluation of the INSTENT 
Evaluation of Heparin + Dispatch catheter to reduce in-stem 
restenosis vs. no therapy 
NA 
Evaluation of PICA with Reopro, stenting plus Reopro and 
stenting plus placebo 
Evaluation of Reopro After Stenting to Eliminate Restenosis 
Gianturco Rouhin Stent Acute Closure Evaluation 
Comparison cif Gianturco Rouhin-It stem vs. JJJS in native, 
nonrestenotic stenoses 
Evaluation of Gianturco Rouhin-II stem in abn!ptithreates:d 
closure, SVG disease, restenotic lesions and smaller 
(2.5 mm) vessels 
NA 
Laser Angioplssty Versus PTCA for Reatenosis in Stents 
Compare the Multi-Link stem with the PafmazSchatz stent in 
focal primary native vessel lesions in a l,tJC@patient 
randomized trial 
NA 
Evalua’iion of AVE stent in France 
NA 
Evaluation of JJJS stent for AMI 
Predictors and Outcomes of Stent Thrombosis 
JJ~S vs. PTCA for vein grafts 
NA 
NA 
Evdlu?! lion of AVE stent 
Evahnrfion of adjunctive stentiug after rotational sthcrrctomy 
Stcnt ititithrombotic Regimen Study: comparixut of AM i, 
Cormadin, ASA + ticlopidine, and ASA alone 
Collecr data on nonrandomiaed STARS patienls 
Spanish Trial of Angioplasty Venus Stcnting 
Reduced anticoagulant regimen; JJJS using ASA + ticlopidine 
Morphologic and morphometric characterization by fVUS of 
hnal result of angiogruphically successfu! high pressure slcnt 
deployment 
Trial of Angioplasty and Stems ~$1 Canada 
Translumioal extraction atherectomy vs. steming 
Wallstent evaluation 
NA 
Wifztor stcnt vs. Gianturcbr Roubin stem for ahmpt closure 
R 
Registry 
Registry 
R 
Pilot 
R 
NA 
R, PC 
R 
NA 
R 
Registq 
NA 
R 
R 
NA 
Registry 
NA 
Pilot 
Retrospective 
Registry 
R 
NA 
NA 
R 
Registry 
R 
Registrv 
R . 
R 
Registry 
R 
R 
Pilot 
NA 
R 
WQO D. B&q 
SO0 F. Litvack 
200 Z. Hijazi 
417 P. SetToys 
6F-K!4! R. Beyer 
50-100 H. Hong, M. Leon 
426 LM. Rothmao 
2,100 E. Topol 
282 S. Ellis 
NA P. Serruys 
7OJtl GR-II 
NA N. Leon 
NA 
NA 
1,IxK) 
J. Popma 
M. l.eon 
D. Bairn 
NA P. J. de Jaegere 
NA WA 
NA G. Stone 
NA G. Stone 
100 P. Ywk 
XII M. Leon 
N.A M. Haudc, R. Erbel 
NA P. Teintein 
600 R. Ilcuscr 
Kk? M. l.ml 
I ,m M, Leon. 1). Bairn 
NA M. l-con 
452 A. Betruit 
NA4 S. Goldberg 
132 P. Fitxgcrald. P. Yock 
270 
NA 
NA 
NA 
NA 
1. Pcml 
M. Parks 
M. Leon 
H. Emanfluelsson, P. Serrqs 
J. Popma 
‘See Table 1. AM1 = acute myocardhd infarction: ASA = aspirin; BENESTENT = Belgian Netherlands Scat Study: DISTRESS = Dispatch Stent Rmtenosis 
Study: EASJ = European Antiplatclet Stent Investigation; HIPS = Heparin Delivery With the lnfusasleeve Catheter i ..“. .- /,._ ?-r-r ‘2% Stew! Implantation; IVUS = intravascular 
ultrasound; JJlS L- Johnson C Johnson Interventional Systems; MUSK = Multicenter Ultrasound Stent in Coronary Artery Disease; NA = not avdilahk at this time;’ 
PAM1 = Primary Angioplasty in Myocardial Infarction trial; PC = placebo comrolled; PTCA = percutaneous transluminal coronq angiopla%y; R = randomize& 
RAVES = Reduced Anticoagulation in Saphenour Vein Graft Stent trial; REST = Rcatenosis Stem Tri& SCRlPPS - Scripps Corona@ Radiation to lnhihit 
Prohferation Post Stenthtg: SMART = Study of Micro-stern’s Ahihty to Limit Restenosis Trial; SPORT = Stent fmpianlation Post Rotational Atherectomy Trial: 
STARS = Stunt Antithromboric Regimen Study; STRESS =1 Stem Restcnosis Study; STRUT = Stent Treatment Region Assessed by Ultrasound Tomography: SVG = 
saphenous vein graft: TECBEST = Transhmrinai Extraction Catheter Be-fore Stem; WEST = West European Stent Trial. 
differences in mortality, stroke, MI, CABS;, functional dass &r 
ang+a or prescribed medication. 
These clinical trial resufts are supported by regiStry ~rkt?’ ‘: 
from the Palmaz-Schatz Stent &tidy Grqup (23) data;@ 3!$: ,i> 
,, _1 :I._ ‘4 r fr, , ,lS,.I.~ 2: >_ 1. ! 1 ,>‘I ‘!I ,I 
results in ‘STRESS (2’1) and BENESTENT (22) trials sag- 
g&ted that the &inical benefit observed at 6 to 7 months was 
maintained. The requirement fof repeat angioplasty was sig- 
,@kantly tower in the SW group, but there were no significant 
;#1 
‘;i ; ; ; ,i ! L 
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nonrandomized patients followed for angiographic outcome at 
6 months and clinical outcome at 1 year. Death occurred in 
0.7%, nonfatal MI in 3.7%, need for CABG in 8% and repeat 
PICA in 13%. Eighty percent of all patients and 87% of those 
without a previous intervention were event-free 1 year after 
stenting. Angiographic restenosis (~50% diameter stenosis) 
occurred in 14% of patients without a previous intervention 
and in 39% of those with previous PTCA. RecentlyV results of 
a 3-year follow-up observationai study of she Palmaz-Schatz 
stern in 143 patients were reported from Japan (24). Survival 
free of MI, CABG and repeat revascularization was 74.8% at 
3 years. There was late improvement in lumen diameter at 3 
years in 72 lesions with paired angiograms. Similar findings 
were reported in 26 patients restudied at 28 months in a report 
from Canada (25). These follow-up studies also suggest that 
restenosis rates in patients receiving stems may be lower than 
in those undergoing PTCA alone. Ciinical event rates (e.g., 
death and MI) >l year have not been reported in enough 
patients to comment on. In particular, the potential adverse 
effect of a metallic intravascular prosthesis on the surface of 
the beating heart over many years is entirely undefined. 
Recommendations, Based on the above data, the consen- 
sus of the Writing Group is that stenting with the PaImaz- 
Schatz stem to improve the angiographic and acute as well as 
‘intermediateterm clinical outcomes of PTCA for short, non- 
restenotic lesions in larger, native coronary arteries is of value 
(Table 3). The Writing Group cautions that this conclusion 
does not neces&ily apply to patients in whom either the 
technical procedure (e.g., high pressure balloons, reduced 
anticoagulants, multiple stents) or lesion characteristics (e.g.? 
restenotic or long lesions) are different from those used in the 
STRESS or EIENESTENT trial. In these subgroups, additional 
data are necessary. Furthermore, long-term clinical outcomes 
are still undefined. 
To Treat Actate or Threutened Closure 
Acute or threatened closure remains an important problem 
for PTCA and other corona?/ interventional procedures (e.g.,, 
atherectomy, laser). Acute closure is usually defined as Throm., 
bo’lysis in Myocardial Infarction (TIMI) grade 0 or 1 flow after 
PTCA. The definition of threatened dosure, which is more 
problematic (26), may include one or more of the following: 
250% residual stenosis, dissection ~1.5 mm in iength, extraht- 
minal contrast, angina or electrocardiographic (ECG) changes 
of ischemia. The incidence of acute or threatened closure 
ranges from 4% to 10% in PTCA cases, without nn important 
decrease over the past 15 years, Acute closure results most 
frequently from dissection and thrombus and le,ss conn~&y 
from coronaty spasm or distal emboltiation. Closure is associ- 
ated with a 25% to 30% incidence of Q wave MI and even 
higher rates of non-Q wave MI. 
,&Me reds, Data from observational reports (27,28) and 
subsequent multicenter registry reports compared with that 
from histdricai control subjects (29) suggest that stems may 
decmase ‘the need for-emergency CABG in patienmwith either 
:_ * ‘1 I , 
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acute or threatened closure. Bccausc there are no adequate 
studies of alternative therapies (e.g,, perfusion balloon and 
CABG) for acute or threatened ciosure, the impact of stenting 
on clinical outcomes cannot be more objectively assessed. 
Furthermore, the frequsncy of acute closure after untreated 
threatened closure is undefined. It is also important to note 
that if CABG is needed after stenting, the stent could poten- 
tially interfere with placement of the distal anastomosis. 
Although the rate of successful deployment is high (>90%) 
and acute angiographic results appear excellent when the stent 
is deployed successfully, the clinical outcomes are less favor- 
able for abrupt closure than for elective stenting. Compared 
with PTCA, there is an apparent reduction of subsequent 
ischemic events. However, there also has been a subacute 
thrombosis rate of 8% to 15% and access site complication 
rates of 10% to 30% (in a period of aggressive anticoagulation 
and possible underdeployment ‘of some stents). Ischemic 
events at 90 days have also been more frequent in patients who 
had urgent (20%) compared with efective stenting (9% p = 
0.0004). Although there were no differences in mortality, 
nonfatal MI was detected 10 times more frequently in the 
urgent deployment group. Predictors of subsequent ischemic 
events are emergency stent placement, smaller stent diameter 
or greater residual stenosis by the deployed device. 
The potential lower nonfatal MI and mortality rates with 
stents compared with those for emergency CABG may be 
related in part to more rapid reestablishment of flow. The need 
for immediate CABG has been greater in patients undergoing 
urgent stenting for acute or threatened closure (12% vs. 6%, 
p = 0.02) (29). For some patients, therefore, emergency 
stenting may be only a “bridge” to CABG. Experience suggests 
that other catheter-based approaches to treatment of acute or 
threatened closure, including perfusion balloons and dircc- 
tional atherectomy to remove small dissection flaps, arc not as 
reliable as stenting, 
kcommendations. Based on axdlable data, the consensus 
of the writing group is that stenting is of established value in 
emergency treatment of either acute or threatened coronary 
artery closure. complicating PTCA (Table 3). The group cau- 
tions that emergency surgery may still be required in some 
cases (e.g., dissection involving the left main coronary artery or 
bifurcations, refractory thrombosis, loss of guide wire access, 
inability to traverse lesion with stent). In addition, there is a 
need for an intense anticoagulation regimen when stents are 
used for this indication. Finally, there are no long-term 
follow-up data, 
To Treat Lesions With High Risk for Closure or 
Suboptimal PTCA 
Stents have been used prophylactically in patients with 
lesions thoaght to be at high risk for acute or threatened 
closure. During PICA, lesion characteristics, such as eccen- 
tricity; irregular borders, ostial location or location on acute 
bends, are associated with an increeased risk for closure. In 
contrast, data from controlled trials suggest that prospective / 
I 
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To prevent angiograpltic and clinical restenosis 
Other indications 
To treat ostial stenosis or LMCA stenosis 
To treat chronic total occlusion 
To treat aortocoronary SVG stenosis 
To treat AM1 
To freat restenosis after PTCA 
To treat rcstrnosis after stcnting 
To treat long lesions or diffuse disease 
High prcsswre balloon intlarion 
1vus 
w-w -- 
Economic Impact 
- 
Economic considerations 
T&k 3. Table of Recommendation.; ior Coronary Artery St&s 
^- __I-- 
Clinic;-i Use Consensus Recommendations 
--^Ix ______ 
Tc improve angioxraphic aed clinical outcomes of Pl’CA 
Intermr&ate-term results Stentbg with the Palmaz-Schati: stem ?o improve angiographic and short-term clinical 
outcomes of PTCA for short, nonrestcnotic lesions in larger, native coronary arteries is of 
value. ‘This con&Sian does not necessarily apply to patients in whom either the t&nical 
procedure (e.g., high prcssuce halloons, reduced anticoagulant agents, multiple stents) or 
lesiun chdiaCteIiStiCS (e”g.: reslenotic or long lesions) are differem from those used in the 
STRESS and BENESTENT studies. In these subgroups. additional data are necessary; 
furthermore, long-term clinical outcomes are still undefined 
Acute or threatened closure Stenting is of value in emergency treatment of either acute or threatened closure complicating 
PTC4. Emergency operation may still be required in some cases (e.g., dissection involving 
LMCA or bifurcations, refractory thrombosis, loss of guide wire access, inability to traverse 
lesion with stent). There is need for an intense anticoagulation regimen when stents are 
used for this indicaticn. There are no long-term follow-up data 
Lesions with high risk for closure or with suboptimal Stenting may be of value in selected high risk lesions and with a Suhrpthnat result aiter 
PTc.4 PTCA. A more definitive tzwnclusion requires controlled trials using objective criteria for 
“high risk” lesions 
Stenting is of value for nonrcstmotic lesions in larger coronary arteries to reduce the rate of 
both angiographic rcstenosis and short-term advrrse dinical outcomes, including need for 
repeat revascuiariration. Additional trials are needed to assess longer term outcomes 
Bawd on the lack of either controlled comparison data or larger observationa! studies, no 
conclusion is warranted about the value of stenting for either ostial or LMCA stenosis 
Based oa tack of data, no conclusion about the value of stenting for chronic total occlusions is 
warranted until larger clinical experience and controlled trial data become available 
Based on data from the SAVED study, stcnting nmy be of early value (e.g.. greater lumen 
sire) for treatment of selected short, nor&al: nonrestenotic saphenous vein bypass graft 
stenoses in patients without AMI, thrombus or poor left ventricular function. The aggregate 
clinical outcome appears to be better in stented cases at o-month follow-up. Clearly, 
additional controlled trials with longer follow-up periods are needed, Use of a biliary stem 
in bypass grafts also requires continued rcscarch 
Until more data become available. no conclusion about the value of stenting for patients with 
AMI is warranted 
In the absence of supporting data, stenting may bc considc:ed in selected cases wvith rester&is 
after PICA, especially when either recoil or suboptinnl dilation at initial Pf’C.4 is a major 
contributor to rcstenosb 
Repeat stenting for restenotic Icsions developing within coronary artery stems is not of 
established value 
Untii controlled trial data are avaiiable. the committee concluded that the use of multiple 
(~2) stems for diffuse or wry long lesions cannot be recommended 
licrge groups of atcnt-treated patients do well with a regimen that excludes intravenous 
dextran and oral warfarin. The exact role for ticlopidine, which has important side effects 
(e.g., ncutropenia in 2%-S% of cases), must await rest&s of controlled trials currently in 
progress. Based on limited data, the committee supports Ihe aspirin-ticlopidine 
anticoagulation regimen in patients with 23smm arteries without evidence for tbrombus, io 
whom the stent has been optimally deployed. if any of the above are absent or if the Stent 
WtS used for abrupt &sore, a full anticoaguhition regimen is reCWnmended 
Based on experience supported by a small body of peWred observational data, optintat 
deployment of the stunt is e~ential, and high ptvlssurc balloon inflation appears to be one 
reliable method to achieve this result 
Until large obsetvational and controlled-trial data become available. IVUS as an adjunctive 
approach to guide stent placement should be applied cautiously and only in selected cases 
Consensus Recommendations 
- -I- 
Based on changes in stenting practice and carts, conclusions about ecwrnomic impact, are not 
appropriate at this time, Because available rconom% data for stents are limited IO de&e 
procedures performed in clinically stablc patients with short target lesions in large proximal 
vesxb, it is currently not possible to projeW effects of stent use in other settings. Use of X! 
srents for a long lesion, combined with PTCA of lesions in other vemels too small fat a 
stem, ail substantially increase procedure costs 
LMCA = left main coronary artery; SAVED = Saphcnaus Vein De NOYO: other abbreviations as in Table 2. 
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assessment of risk for closure cannot be done with high 
reliability, Many experienced operators, including members of 
the wri@ committee, believe that the result of PTCA in these 
lesions is less predictable than that obtained with stems. 
Nowever, there are still no controlled trial data to support this 
opinion. 
The stable but suboptimal PTCA lesion also is at higher risk’ 
(30). Because a small minimal lumen diameter after PTCA 
predictsa higher restenosis rate, it is possible that use of a stent 
to increase the lumen diameter could improve late outcome. 
This rationale is being tested in a muiticenter trial comparing 
stenting for suboptimal PTCA versus conservative treatment 
(Tabb 2). 
Recolrxmendstions. The consensus of the writing group is 
th::‘i stenting may be of value in selected stable but high risk for 
closure lesions and with a stable but suboptimal result after 
PTCA. A more definitive conclusion requires controilcd trials 
using objective criteria for “high risk” for closure lesions. 
To Prevent Aq$ographic and C/i?lical Restenosis 
Angiographic restenosis after PTCA of large arteries with 
restenotic lesions occurs in 30% to 50% of patients, and repeat 
revascularization is required in -20% to 30% of all PTCA 
cases (31,32). Randomized, controlled trial data suggest that 
stents decrease both the rate of angiographic restenosis and 
the need for repeat revascularization compared with PTCA 
alone. In the STRESS trial the restenosis rate was 31.6% with 
i&a! stenting versus 42.1% with initial PTCA (p = 0.046) and 
that for the BENESTENT trial was 22% with &niing versus 
32% with PTCA (p = Ml2). Smaller studies of selected 
patients with serial follow-up data suggest that the angio- 
graphic improvement is sustained at least over 1 to 3 years 
(22,24,25). Long-term data are not yet available, 
Recommendations, Based on the available data, the con- 
sensus of the writing group is that stenting is of value for 
nonrestenotic lesions in larger coronary arteries to reduce the 
rate of both angiographic restenosis and related short-term 
adverse clinical outcomes, including the need for repeat revas- 
cularization. Additional trials are needed to assess longer term 
outcomes. 
Other Potential Indications for Stenting 
To treat ostial or left main coronary stenosis. Neither 
A biliary stent with greater radial compressive strength, 
enhanced visibility, larger diameter and variable length was 
used in 123 saphenous vein bypass graft lesions by Wong et al. 
(4Oj. In this retrospective single-center review, favorable short- 
and long-term outcomes similar to those obtained using the 
Palmaz-Schatz coronary stent were reported. Although the 
biliary stent offers greater fluoroscopic visibility, this use is not 
FDA approved, and results are highly operator dependent 
P-4. 
A multicenter randomized, controlled-trial (the Saphenous 
coronary ostial stenosis nor left main stenosis is easily treated Vein Graft De Nova [SAVED] study) compared stcnting 
with PTCA. An uncontrolled observational study (33) of 41 (Palmaz-Schatz) with PICA for nonrestenotic lesions (41) that 
patients with ostial stenosis of either native coronary arteries are relatively short in length (e.g., requiring no more than two 
or saphenous vein ‘grafts suggested that stenting can be per- stents), in vessels 3.1) to 5.0 mm in diameter, nonostial and not 
formed ,with good angiographic success rates. However, 7.3% 
of patients had procedural complications, -5% died in the 
associated with acute MI (7 days) or angiographic evidence of 
thrombus in patients without poor left ventricular function. 
hospital, and 28% developed late restenosis. Others have Patients also ‘had to have angina and/or evidence for myocar- 
reported (34) that stenting of ostial stenoses of saphenousvein dial ischemia and no comraindications to anticoagulation, 
bypass grafts is associated with a high restenosis rate, but there 
are no controlled studies with longer follow-up comparing 
evidence for outflow obstruction due to, distal anastomotic 
stentingwith,other 
stenosis or poor contrast flow in the native vessel. Thejpost- 
: proven elIective treatments,such as CABG. procedural minimal. lumen diameter was 2.81 mm: with.the: ‘. _ : ;: I :I, I/, d. /( ,: ‘, [,. ,::” ,,, 4 “8 . ‘~ /! , _, ! :: ~, ii: : : ,, : : ‘i ,* : 1. /I ,,, . ..‘?a ; _ : i : ,:; :,. :.i.i. ‘I !,i, II ) I ; r ; : ::.t,.<. c,:,+ 
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Recommendations. Based on the lack of either controlled 
comparison data or larger observational studies, the consensus 
of tne writing group is that no cczziusion is warranted about 
the value of stenting for c&her ostial or left main stenosis. 
To treat ckroiais totaR occlusion. In treatment of chronic 
total coronary occlusion, PTCA alone results in ‘either failure 
to cross the occlusion or an unsatisfactory angiographic result 
in -40% of cases (35). The restencsis rate is also high. When 
angioplasty successfully opens a vessel, experienced operators 
have observed that the addition of a stent reduces recoil, 
irregular residual lumen. dissection and residual stenosis. 
Limited obseniational data suggest that reocclusion and resten- 
osis may also be reduced (36). There are no large-scale 
observational reports, controlled studies or long-term angio- 
graphic reports and no adequate reports of cliaical follow-up. 
Recommendations. Eased on lack of data, the consensus of 
the writing group is that no conclusion about the value of 
stenting for chronic total occlusions is warranted until larger 
clinical experien .e and controlled trial data become available. 
To treat aortororonary saphcnous vein graft sterosis. 
Corollary angioplasty of saphenous vein graft stenosis, com- 
pared with native arterial stenosis, is associated with increased 
rates of acute clinical events and restenosis. An observational 
multicenter study (34) of 198 patients reported that elective 
Palmaz-Schatz stent placement was associated with a high 
initial success rate (98.5%) and a 34% angiographic restenosis 
rate at 6 months. Seventy percent of patients were event free 
(death, lUI, need for CABG or repeat PTCA) at 6 months. 
Another observational sag= m”- .+“, , ,+rted an angiographic resten- 
osis rate of on!y 21% after Palmaz-Scha+z stem implantation 
(37). These ‘rates are lower than those previously reported for 
PTCA of vein grafts. There appear to be important subgroups 
within this population: Patients with ostial and restenotic 
lesions nad a higher rate of restenosis and cardiac events than 
the overall group (34,38,39). 
JACC Vol. 28, No. ; 
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stent versus 2-X mm (p < 0.0001) with PTCA. The patients’ dure lumen diameter, diabetes mellitus and use of multiple 
average age was 66 years, and the mean vein graft age was 10 overlapping stents (45). Restenosis occurring within stents ;s 
years, with a mean diameter of 3.19 mm. Technical sticcess more frequent when stents are used for restenotic than non- 
(~50% stenosis by quantitative coronary aagiography) was 
95% with a stent btzt only 75% with PTCA (p < 0.0001). 
restenotic lesions. Although there is no published experience, 
there was little support for repeat stenting of restenotic lesions 
Clinical success (defined as technical success without an in- that develop within stents, Committee members believe that 
hospital major cardiac event) was 92% with a stent and 69% restenosis within a stent is probably better cpprsached with 
with PICA (p < 0.0001). There were fewer non-Q wave MIS in PTCA or with an excimer laser. 
patients with a stent (two vs. seven patientc, p = O.Ol), whereas Recommendations. In consideration of the lack of data, the 
Q wave MI, death or need for CAJ3G occurred at simi9ar rates consensus of the writing group is that use of repeat stenting for 
in each treatment group. The need for transfusion, however, restenotic lesions developing within coronary artery stems is 
was greater in the stented group (11 vs. 1 patients, p = 0.003). not of established value. 
At 6 months, in the stent group late loss was greater (I.04 vs. To treat long lesions @r ditke disease. There haye &en 
0.68 mm, p = O.Ol), but net gain was significantly (p = 0.015) some applicatiorbs of mtiltiple (more than two) stents to cover 
greater (0.87 vs. 0.52 mm) than in those with PTCA. The major diffuse or very long lesions. There are no suitible observational 
cardiac event (death, MI, need for repeat revascularization) or controlled trial data to evaluate this application. Frcim 
rate at 6 months was 26% after stenting compared with 38% experience, however, the committee notes that the potential 
after PTCA (p = 0.05). These data indicate that stents may be for stent thrombosis increases with multiple stents, and con- 
preferred to PTCA in selected, nonrestenotic vein graft le- trolled trial data would be required in cases using more than 
sions. two stents in order to support a recommendation. 
Recommendations. Based on data from the SAVED study, Recommendations, Until controlled trial data are avail- 
the consensus of the writing group is that stenting may be of able, rhe committee concluded that the use of multiple (more 
early value (e.g., greater lumen size) for treatment of selected than two) stents for diffuse or very long lesions cannot be 
short, nonostial: nonrestenotic saphenous vein bypass graft recommended. 
stenoses in patients without acute MI, thrombus or poor left 
ventricular function. The net gain WE greater and the aggre- 
gate clinical outcome better in stentcd cases at &month Ge~eralizability of Current Knowledge 
follow-up. Clearly, additional controlled trials with a longer Because stems diifer substantially in design and materials. it 
‘follow-up period are needed. The writing group felt that the is not appropriate to extrapolate the very limited tintroiled 
‘use of a biliary soent in bypass grafts requires continued trial results obtained with one stent to another stent. In 
research before a recommendation could be supported. addition, benefits of stenting have been obsemed in a highly 
To treat acute Ml. There are nl!y a few sing!e+nter &e&d, tiiriicaiiy stable subset of patients with coronary, 
small-volume observational reports on the use of stents in artery disease, and only short- and immediate-term fesults’ 
acute Ml (42-44). Although stenting may have a role in have been reported, The reported benefit is restricted to 
carefully selected patients in whom direct PTCA for acute MI nonrestenotic lesions in the proximal to midportions of larger 
fails, controlled trial and observational data are required to native coronary arteries. The benefit consists of ieduced need 
evaluate stenting results with those after emergency bypass for repeat revascularization procedures. Whereas beneficiai 
surgery before a recomniendation could be supported. results are also likely to exist for venous bypass grafts that are” 
Recommendations. Until more data become available, the approximately ~3.0 mm in diameter wiith relatively short, 
consensus of the writing group is that no conclusion about the nonrestenotic lesions, these lesions must have other character- 
value of stenting for patients with acute MI is warranted. istics that will permit stent delivery. The value oi stenting in 
To treat restenosis affer PICA. Restenosis after PTCA different clinicat or anatomic subsets (e.g., acute ischemic 
and other coronary interventional procedures occurs in 30% to syndromes, arteries g3.0 mm in diameter,’ lesions requiring 
50% of cases. There are no data from controlled trials or large more than two stents, restenotic lesions) is as yet not known. 
observational studies for this subgroup. Because restenosis 
may OCCUF at increased frequency when restenotic lesions are 
Finally, it is important to note that patients in the clini+Jy 
stable ‘phase of coronary artery disease fre@ently, haye ,Lfe, 
stented; a controlled trial would be required to determine if expectancies of $5 to 20 yea& Stents remain iln tl;e coronarjr 
benefit occurs in this patient subset.’ vascular system of these patients, on the surface of the beating 
~~rnrne~~.at~~~s~ In the absence of supporting data, the heart. The potential long-term adverse effects of th&e device!: 
writjng gryup &cussed their experience. The group speculated could be unknown for mar&years. ,. ‘~ 
that ‘st&tmg may be ionsidered:,in seleeteg cases with resten- 
8 :4 
osis afier PTC& especiaily;when eit!& recoil or stiboptinial 
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substantially. At one extreme is the position that every patient 
with the high risk clinical or anatomic characteristics noted 
above and who needs PTCA should receive a stent. With this 
unrestricted strategy, steating is performed prophylactically to 
provide each patient the best chance of both early and late 
success. Inherent in this approach is the unnecessary use of 
stenting. Many patients who would not have an unfavorable 
outcome with PTCA alone would nevertheless receive a stem. 
One might estimate that such a strategy would result in 
unnecessary stent use in -50% of cases. Furthermore, these 
cases would have a device implanted for life, when there is no 
information about long-term performance. 
Stem cases at high risk for early thrombosis (e.g., thrombus, 
poor runoff before or after stenting or residual dissection or 
stenosis after stenting) are treated with the more intensive 
anticoagulation protocol. In many centers, warfarin is now 
reserved for patients with procedural complications or those 
without an optimal angiographic or intravascular uitrasound 
appearance. 
An alternative strategy is to use stents only for a poor result 
with PICA. With this selective strategy, stents are restricted to 
comphcations of the preceding angioplasty. This approach 
minimizes both the financial cost and adverse clinical outcomes 
of stenting but may deprive some patients of prophylactic 
benefits in terms of reduced risk for restenosis. A third strategy 
lies between these extremes. Clearly, controlled trial data 
comparing these strategies are required. 
Beyond actual stent delivery and deployment, there are 
important ongoing changes in adjunctive pharmacotherapy 
and interventional technology. 
There are no published controlled trial data to confirm that 
prevention of subacute thrombosis with aspirin and ticlopidine 
with or without low molecular weight heparin is equivalent or 
superior to aspirin alone. A large randomized trial to assess 
differences behvcen aspirin, aspirin plus ticlopidine, and cou- 
madin as adjunctke agents with the Palm&r-Schatz stent is 
ongoing (Stcnt Antithrombotic’ Regimen Study [STARS]) (Ta- 
ble 2). The Reduced STRESS trial is an observational study 
addressing angiographic and clinical outcomes of elective 
Palmaz-Schatz stent placement with high pressure balloon 
inflation and lessened anticoagulation, using the same inclu- 
sion criteria as in the original STRESS trials. Currently, the 
FDA recommends use of the aggressive anticoagulation pro- 
gram because there is only one controlled trial with data 
available to support the use of aspirin plus ticlopidine. Tile 
FDA has maintained that exceptions to this program represent 
‘“off label use” of stents in coronary arteries. The FDA has 
approved the investigational use of ticlopidine and aspirin for 
the trials under way. In contrast, the anticoagulation used in 
the original ‘STRESS and BENESTENT trials was associated 
with a high rate of vascular complications related to prolonged 
heparin use while ‘waiting for the antithrombotic effect of 
warfarin to develop. 
patients were randomized to either antiplatelet therapy with 
aspirin plus ticlopidine or to anticoagulant therapy with hep- 
arm, phenprocoumon aud aspirin. At 30 days, t’ : antiplatelet 
ticlopidine, which has important side etiects (e.g., neutropenia 
in 2% te 3% of cases), must await results of controlled trials 
thempy group had a significant reduction ‘in’ risk for MI, need currently in progress. Based on Iimited data, the committee 
fop a repeat intervention, peripheral vascular events and 
oc’clusion of the stented vessel. Consequeutly, many operators 
supports the aspirin-ticlopidine anticoagulation’ regimen in 
itl the United States have reduced the intensity of anticoagu- 
patients with ?3-mm diameter ,arteries without evidence for 
latiori in selected patients at low risk for stem thrombosis. 
thrombus, in whom the stent has been optimally deployed, If 
Heparm is given only during the procedure, and accesssheaths 
any of the above are absent or the stem was used for ab&,7jpt 
closure, the full anticoagulation regimen should be considered, 
are removed as soon as the activated clotting time reverts to 
normal, usually iu -4 h. Aspirin (325 mglday) is used routinely, 
High pressure b@qm @d&&ion. Routiae9y; after a stem is 
,aud: ticlopidine. (Ticli$, 2.50 mg twire a clay) is used by some 
deployed, balloon inilation is performeb’ wit&i the stem to 
~J?y$toe fO! -$yth,;“$” have u&$lv rrmctlecy!!y weight 
ensure uniform cir$urtferential .e~pansion and .$im,al appo- 
,~~,~~~~~,~~~~~~ v@~~f~~~~ TV. $-w+$$ ~loprdme(47). 
sition of the stem to $be vessel wall. This,pro&iure,,u&lin the” _, :, 
,J*:,;,.;,,;;,,!: i 1 ‘. i’-,“,’ ,JC,,,‘;:’ :., . ,),I! :,! ‘, , : 
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Pharmecatherapy. Because of possible subacute stem 
thrombosis, intense anticbagulationlantiplatelet therapy be- 
came the standard with stents used in the United States. 
Initially this regimen consisted of preprocedure aspirin and 
dipyridamole, intraprocedure and postpro&cre heparin and 
low molecular weight de&an. Warfarin was stsrted just before 
or immediately after the procedure and continued for 2 to 3 
months after the procedure, along with aspirin (with or without 
dipyridamole). Aspirin (with or without dipyridamole) was 
continued indefinitely. Several recent observationa reports 
from Europe (46-48), however, have suggested that such 
intense anticoagulation may not be necessary when high 
pressure balloons result in full stent apposition with the vessel 
wall, This was confirmed in the Intracoronary Stenting and 
Antithrombotic Regimen (ISAR) trial reported from hlunich 
(49). After successfcll stent (Pa9mazSchatz) placement, 517 
A second emerging factor in anticoagulant strategy is local 
drug delivery. A hepariu-coated Paimaz&haa stent has re- 
cently been reported to be very we9I tolerated in the 
BENESTENT-II Pilot Study (SO). The implantation of stents 
coated with polyamine end-point-attached heparin in stable 
patients with nonrestenotic lesions was associated with no 
episodes of acute or subacute stent thrombosis and a favorable 
event-free survival after 6 months with use of only the ticlopi- 
dine and aspirin regimen. 
Recommendations. It is clear from observational reports 
that large groups of patients treated with stenting do well with 
a reduced anticoagulant regimen that excludes intravenous 
dextran, oral warfarin and prolonged bpparin. The role for 
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past 1 to 2 years with introduction of high pressure balloon 
inflation (46,48). In a series of patie:lts undergoing stenting 
with evaluation by intravascular ultrasound, balloons larger 
than the stent size (e.g., a 4.0-mm balloon with a 3.5.mm stent) 
were not as effective as high pressure balloon inflation to 18 or 
20 atm. Although this adjunctive technique appears to improve 
apposition of the stent to the vessel wall, there is the potrntial 
for increased vascular injury, particularly in the segment 
immediately adjacent to the stent. Although high pressure 
inflation after stent deployment is being increasingly per- 
formed, there are no controlled trial data available to assess 
the intermediate and longer term consequences of such a 
strategy. 
Recommeadatious. Based on experience supported by a 
small body of published observational data, the committee 
believes that optimal deployment of the stent is essential, and 
9&h pressure balloon inflatnon appears to be a r&able method 
to achieve this result. More investigation is needed to assess 
the results of this deployment strategy over the long term. 
Other Adjunctive Approaches 
Customizing stents. During angioplasty, some operators 
have modified certain stents in an &fort to fabricate a device 
that they believe is more suitable for a specific lesion. These 
modifications ilrclude cutting, bending and molding, among 
others. Because these practices have not been systematically 
investigated, it is the consensus opdnion of this writing com- 
miFtee that no recommendations should be made until more 
data are available. 
New devices. Although rotablational (ROTA), direction-z! 
(DCA), transluminal extraction (TEC) and laser (ELCA) 
atherectomy have all been used before stenting with the goal of 
plaque debulking @I), these approaches have not been com- 
pared with either debulking alone or stenting and PTCA alone. 
Until such comparison studies are performed in a controlled 
trial, the committee concluded that ihe value and safety of 
combined debulking and stenting yemain unknown. 
Intravascukir uitrasourd. The tomographic orientation of 
ultrasound enables visualization of the full 340” circumference 
of the vessel wall and permits direct measurements of lumen 
dimensions, including minimal and maximal diameter and 
cross-sectional area. Information from ultrasound is additive 
to that obtained by angiography. Because of the latticed 
characFe&Fics of stients, radiographic contrast material can 
surround the’stent, prpducing an angiographic appearance of a 
large lumen, every when the stent struts are nut in full Contact 
with the vesscll wail, A large observational ultrasound study 
>after a~g~o~~a~~ca~~ guided stent depioyrtient (46) revealed 
an average residi@ ,plaque area of .5l$+ in a comparison of 
’ minimal stent diameter with referenck segment diameter, and 
incomplete wall aTposition was frequenaiy observed, In this 
1 cohort, a+litionat ,b&on inflations resulted in a final average 
,. &&~al plaque area &f JA%,,even dough the final angio- 
-! grapbic,pe~~~rit,stenosi~was pe;@tiue (-0,7%). These Yorkers 
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thrombosis rate of only 0.3%, using antiplatelet agents with no 
sysfematic anticoagulation after the procedure. 
Despite the promising results reported in this single-center 
study, caution is warranted. The cases were highly selected, the 
investigation was nonrandomized, and several alternative an- 
tiplatelet regimens were usad. The Iarger area within the stent 
was achieved using more aggressive balloon dilation tech- 
niques with either larger or higher pressure baUoons. Further- 
more, because the impact of more aggressive dilation on longer 
term outcomes has not been examined by prospective, con- 
trolled trials, it is possible that increased vessel wall injury from 
larger high pressure balloons could result in unfavorable 
long-term results. Most authorities recommend that operators 
attempt to achieve a minimal percentage of reference vessel 
diameter within the stent, usually at least 60% cross-sectional 
area by inbavascular ultrasound. In addition, most protocols 
require nearly complete apposition with separation of any stiut 
from the vessel wall not exceeding 0.3 mrr. However, FheFe 
goals are arbitrary and have neither been derived from nor 
tested in controlled trials. 
When stenting is performed for acute or threatened closure 
due to dissection, intravascular ultrasound can be used to 
determine the true longitudinal extent of the dissection, which 
is often greater than is angi~~raphically apparent before 
placement of a stent. How useful this information will be, in 
terms of outcomes versus costs, remains to be determined. 
Furthermore, the safety of passing monorail catheters through 
a fine-wire coil design, such as the Gianturco-Roubin stest, 
remains questionable. 
Recommendations, Until large observational and con- 
trdkd trial data become availabfc, Ihr: consensus of this 
writing committee is that the use of intravascular ultrasound, 
as a routine adjunctive approach to grlide stent placement, is 
still evolving, and its best indications are yet to be fully 
elucidated. Clearly, in selected cases Intravascular ultrasound 
may be of value. 
S&&tics on Econmic Impact 
Ecmaomic Ctmsidethm 
Early ob?e:crvational studies compared stenting with other 
percutaneous techniques. In patients undergoing single-vessel 
procedures, Dick et al. (52) found that hospital charges w&e 
doubled in’patients treated with stenting relative to those $iFh 
PTCA. A more recent observaFionai study by Cohen et al, (53) 
reported that in stable patients undcrgoipg elective proce- 
dures, stenting increased length of hospital stay by -2.5 days 
.:nd medical costs by -%3,000 relative ‘$0 PTCA. izowever, 
initial hospitalVcosts’of stenting remained less than those of 
CABG in comparable patients. 
in Fhe two randomized trials itf stenting versus PTCh, the 
initial hospital stay was significaptiy longer for’ stemtreated 
Fhtan PWA-treated, patients. %tentWa\eti p@nts also h;id” 
more bleeding and, Y@e@ar co&$icaticins; @a$%?!$ i&&d j 
to ant~~oagu~~t,~o~ :&ii$ wa;faj;i$ I! c&+‘; :~~~~~~~~~~ <, $1 ‘;, I’ : .i; ,:: I( i ;,,I c ?. (,i ,; i!; ‘i i !: ,:_ ,, ;. < ,a,: I1 ;, $” i~:.,~,.‘<!;f;& I, e 
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(i-month follow-up period, the stent group had about one-hail’ 
the rate of repeat ievascularizations observed in the PTCA 
group. Thus, relative to PTCA, it is reasonabie to conclude 
that stenting has higher initiai but lower follow-up costs. 
A subset of U.S. STRESS sites participated in a prospective 
cost substudy involving 207 of ?he 410 patients enrolled. 
Detailed analysis of medical costs was p~;:~~rned by Cohen et 
al. (54) using rhe latest costing methodology. Resource usei 
costs were measured for 1 year after enrtillment. They identi- 
fied three major areas of cost differences between stenting and 
PTCA: procedural, postprocedural in .ho$tal and :>llow-up. 
Cath:[erization laboratory resource use during the initial 
procedure was higher for the stent group (e g., more stents, 
FTCA catheters, ‘radiographic contrast) despite a similar over- 
all procedure duration. Consequently, iaboratory costs aver- 
aged -$1,200 higher for the stent group ($4,691 vs. $3,505). 
The length of the initial hospital stay was significantly 
greater for stent-treated than PTCA-treated patients (7.5 days 
total [5.8 post procedure] vs. 4.8 days total c3.5 post proce- 
dure]), The increased length of stay added an average of 
almost $1,2ilO to the cost of the stent arm, primarily due to 
more room,‘nursing time, laboratory tests and pharmacy costs. 
From hospital discharge to 1 year, the stent group had 
fewer repeat revascularization procedures and cardiac-related 
readmissions to the hospital but more readmissions for bleed- 
ing related to anticoagulation. Total l-year follow-up care 
costs thus tended to be lower in the stent than ,the PTCA group 
($1,918 vs. $3,359, p = 0.21). Combining the initial hospital 
stay and follow-up medical costs, the stcnt arm had an $800 net 
higher I-year cost than PTCA ($11,656 vs. $10,865, p < O.OOI). 
Despite providing the best data available, at least five 
factors reduce the relevance of these data from patients 
treated between 1991 and 1993: 1) The Palmaz-Schatz stent 
currently costs $400 more than was assumed ($1,600 current 
price vs. $1,200 in the STRESS Economic Substudy). 2) 
Changes in stent procedure with increased use of intravascular 
ultrasound to, guide decisions about adequacy of deployment 
and high pressure balloons have increased catheterization- 
related costs. Suskin et al. (55) estimated this to average 
-$1,50O/stent-treated patient. 3) Current trends to substitute 
aspirin-ticlopidine for aspirin-heparin-warfarin appear to 
have lowered bleeding and vascular complication rates, possi- 
bly without an increase in abrupt closure rates. Thus, most 
stem-treated patients are not likeiy to require more days in the 
hospital than PICA-treated patients. Reduced postprocedural 
hospital stays and vascular complication rates would save 
-$I,000 in room/nursing and other related costs for stent- 
treated patients. 4) Assuming that omission of warfarin prc- 
serves the foilow-up benefits of stenting, such a strategy would 
be expected to reduce the need for repeat, hospital admissions 
arising from warfarin-related hemorrhage. Reduced readmis- 
sion for bleeding would be expected to save -$300 to $500 
~ ‘(assuming a total cost for such admission of $6,000 to $10,000). 
5) Clinical results with stents are likely to have improved since 
2’ the :STRESS trialwas conducted; because- more recent data, 
_I although, unconti,olled,, suggest restenosis ratesaslow ,as 1.5% ,- , : s, .j / 81 /_ ,i , ii I,,‘, ,( . 
1 j;, +J; :.,, ,:;I”: ;; 1 /: . i ~ : , ‘, 
.I I .I: : 
,, / ! I’,: ‘. I ; 1 .:::i ! j ” ,i .: ! 
to 20% (vs. 31.6% in the STRESS trial). Further reductions in 
need for repeat revascdarization might be expected to reduce 
costs by $609 to $ROO (assuming an average follow-up cardiac- 
related hospital stay cost of $6,000 tc $8,000). 
The net effect of these factors on the costs reported in the 
STRESS Economic Substudy would project ‘io an estimated 
cost difference at 1 year between cost saving for stenting at one 
extreme to -$3,OOO in extra costs at the other extreme. The 
ongoing BENESTENT II study, includes an economic compo- 
nent and should provide important new data relevant to this 
issue. 
Stents have been successfully substituted for emergency 
CARG in some cases of abrupt closure after PTCA. Five 
percent of PTC.4-assigned patients in the BEldESTENT trial 
and 7% in the STRESS trial received an emergency stent. Use 
of the stent for this indication would tend to lower the cost for 
PTCA by about ~$1,000 because the cost of emergency 
surgery can be high (e.g., $27,000 in the Evaluation of IIbbiiIIa 
Platelet Receptor Antagonist 7E3 in Preventing Ischemic 
Complications [EPIC] trial). No large-scale studies of the 
potential cost-saving effects of stenting for inadequate PTCA 
have yet been published. 
Recommendations. Based on changes in stenting practice 
and costs, the committee believes that conclusions about 
economic impact are not appropriate at this time. Because 
available economic data for stents are limited to elective 
procedures performed in clinically stable patients with short 
target lesions in large proximal vessels, it is currently not 
possible to project the effects of stem use in oth.er settings. Use 
of two stents for a long lesion, combined with PTCA of lesions 
in other vessels IGO small for a stent, can all substantially 
increase the cost of the procedure. 
eralizing these findings to other situations for which coronary 
stenting is considered. We are concerned about the rapid 
proliferation and application of this technique to very large 
groups of patients without adequate supporting data, particu- 
larly those patients with stenoses other than nonrestenotic 
lesions in large vessels. In addition, we are concerned about the 
lack of intermediate- to long-term follow-up data, especially 
with regard to non-Q wave l$I and mortality. We strongly urge 
interventional cardiologists to practice caution wherrconsider! 
ing application of coronary stems until more cantroIled triai, 
data are available. Particular caution shoulclbe extended in use 
of s,tents,in:scena$os where benefit .ht,not been prr+dj such : 
( ,‘i _ , : I 
’ ~,,’ 
j s ‘it,i’ ; 1% r,:’ ; : i zr $; i‘ i _j : :;:i ~’ ;,j ;:‘” : ,_I ! ,i,’ L Fil ‘; __/) “( :Li: I,, 
,,i ,/I- /
* $,I, ;: ‘,/I) i,I
Summary and Cautions 
In summary, the committee concludes that elective stenting 
in selected patient subsets enhances the result of percutaneous 
coronary interventional procedures. In these subsets, the 
Palmaz-Schatz stent, used electively, reduces the risk for 
restenosis and need for repeat interventional procedures com- 
pared with PTCA alone. When used for acute or threatened 
closure, stenting reduces, but does not eliminate, the need for 
emergency CABG. 
The committee also strongly recommends cantion in gen-’ 
JACC Vol. 28, No. 3 
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as treatment of ostial or left main coronary artery lesions, small 
vessels, chronic total occlusions, acute MI, restenotic lesions, 
long lesions or d&se disease. 
The Writing Group of the Expert Consensus Document on Sterns and the 
Cardiac Catheterization Committee wish to thank Bram Zuckeonan, MD, 
FACC and numerous outside reviewers for assistance in the preparation of this 
document. 
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